IP Library Granted Patent US 9,163,211
Granted Patent B2
US 9,163,211 · App. 13/960,481 · Granted Oct 20, 2015

Animal protein free media for cultivation of cells

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,163,211
App. No.
13/960,481
Granted
Oct 20, 2015
Kind
B2
Abstract

The present invention relates to animal protein free cell culture media comprising a combination of non-animal derived peptides derived from soy hydrolysate and yeast hydrolysate. The invention also provides an animal protein free culture process, wherein cells are cultivated, propagated and passaged without animal-derived components. This process is useful for cultivating cells, such as recombinant cells or cells infected with a virus, and for production biological products by cell culture processes under conditions devoid of animal protein components.

Claims (8)

1. A method for producing a virus, comprising:

growing a culture of VERO cells in an animal protein free medium comprising soy hydrolysate at a concentration of about 0.05% (w/v) to about 1% (w/v) and yeast hydrolysate at a concentration of about 0.05% (w/v) to about 0.3% (w/v);

infecting the VERO cells with a virus; and

incubating the infected VERO cells to propagate the virus.

2. The method of claim 1 , wherein the virus is selected from the group consisting of vaccinia virus, coronavirus, orthomyxovirus, Ross River virus, Flavivirus, and picornavirus.

3. The method of claim 2 , wherein the virus is an orthomyxovirus selected from the group consisting of influenza A, influenza B, and influenza C virus.

4. The method of claim 2 , wherein the virus is a Flavivirus selected from the group consisting of Yellow fever virus, Japanese encephalitis virus, Tick-borne encephalitis virus, West nile Virus and Hepatitis C virus.

5. The method of claim 2 , wherein the virus is a picornavirus selected from the group consisting of poliovirus and hepatitis A virus.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2021
From: BAXALTA GMBH; BAXALTA INCORPORATED
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 055189/0005 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYING PARTY DATA PREVIOUSLY RECORDED ON REEL 036357 FRAME 0001. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT FROM BAXTER HEALTHCARE SA TO BAXALTA GMBH AND BAXALTA INCORPORATED. Recorded Aug 21, 2015
From: BAXTER HEALTHCARE SA
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036412/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2015
From: BAXTER HEALTHCARE S.A.
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036357/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2015
From: BAXTER INTERNATIONAL INC.
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036373/0001 →